Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
UPDATE: Aurinia Pharmaceuticals (AUPH) PT Raised to $32 at Cantor Fitzgerald; Not Just a Takeout Play
-
Grid Dynamics Goes Public through Business Combination with ChaSerg Technology Acquisition Corp.
-
Investors fret over risks to U.S. corporate credit as coronavirus spreads
-
Optinose (OPTN) PT Lowered to $21 at Cantor Fitzgerald
-
Form X-17A-5 CANTOR FITZGERALD & CO. For: Dec 31
-
Health Insurance Innovations (HIIQ) Sell-Off 'Overone' - Cantor Fitzgerald
-
SymphonyAI Group Acquires Healthcare Imaging AI Technology Leader TeraRecon
-
Aridis Pharmaceuticals Provides Update on Investor Day Featuring Key Opinion Leader Panels on Cystic Fibrosis and Pneumonia
-
SDX Energy PLC Announces Update on drilling operations in Morocco and Egypt
-
Cantor Fitzgerald Starts ZIOPHARM Oncology (ZIOP) at Overweight
-
Tilray (TLRY) PT Lowered to $17.50 at Cantor Fitzgerald Even After Drop There is Room for Disappointment
-
Form X-17A-5 CANTOR FITZGERALD & CO. For: Dec 31
-
Avalon Adds Five Senior Hires to Event Driven and International Equities Teams
-
Mereo BioPharma (MREO) Reports Positive Feedback from Type B End-of-Ph. 2 Meeting with FDA & Outlines Pivotal Ph. 3 Pediatric Study Design for Setrusumab in Osteogenesis Imperfecta
-
Mereo BioPharma Announces Positive Feedback from Type B End-of-Phase 2 Meeting with the FDA and Outlines Pivotal Phase 3 Pediatric Study Design for Setrusumab in Osteogenesis Imperfecta
-
Mereo BioPharma Announces Positive Feedback from Type B End-of-Phase 2 Meeting with the FDA and Outlines Pivotal Phase 3 Pediatric Study Design for Setrusumab in Osteogenesis Imperfecta
-
Mustang Bio (MBIO) Weakness Creates 'Clear' Buying Chance - Cantor Fitzgerald
-
Freddie Mac Prices $580 Million Multifamily K-Deal, K-HG2, Backed by Properties Controlled by Harbor Group International, LLC
-
UPDATE: Cantor Fitzgerald Starts Anavex Life Sciences (AVXL) at Overweight
-
Freddie Mac Prices $870 Million Multifamily K-Deal, K-F75
-
Momenta Pharmaceuticals (MNTA) PT Raised to $30 at Cantor Fitzgerald
-
Pagaya Closes $200 Million Consumer Credit ABS
-
Castlight Health Inc. (CSLT) PT Lowered to $2 at Cantor Fitzgerald Following Earnings
-
Evolent Health (EVH) PT Lowered to $14 at Cantor Fitzgerald
-
UPDATE: Cantor Fitzgerald Starts Arcutis Biotherapeutics Inc. (ARQT) at Overweight
-
UPDATE: Cantor Fitzgerald Downgrades Galapagos NV (GLPG:NA) (GLPG) to Neutral
-
SDX Energy PLC Announces Appointment of Joint Corporate Broker
-
Cantor Fitzgerald Reiterates Overweight Rating on Aravive Inc. (ARAV)
-
HMS Holdings (HMSY) PT Lowered to $33 at Cantor Fitzgerald
-
Pre-Open Stock Movers 02/21: (BXRX) (CRC) (DBX) Higher (TRUE) (BXC) (EYPT) Lower (more...)
-
After-Hours Stock Movers 02/20: (ZIXI) (EHTH) (DBX) Higher (EYPT) (TRUE) (FSLR) Lower (more...)
-
Orchid Island Capital Announces Fourth Quarter 2019 Results
-
Cantor Fitzgerald Starts Celldex Therapeutics (CLDX) at Overweight
-
Energy Fuels Announces Closing of Previously Announced US$16,611,000 Bought Deal Offering
-
Cantor Fitzgerald Reiterates Overweight Rating on Mesoblast Limited (MESO)
-
Cantor Fitzgerald Reiterates Overweight Rating on Heron Therapeutics (HRTX)
-
Reata Pharmaceuticals (RETA) PT Raised to $320 at Cantor Fitzgerald
-
UPDATE: Cantor Fitzgerald Downgrades Tivity Health (TVTY) to Neutral
-
Mereo BioPharma Announces Equity Investment of $3 Million from New U.S. Institutional Investor
-
Mereo BioPharma Announces Equity Investment of $3 Million from New U.S. Institutional Investor
-
Stealth BioTherapeutics (MITO) PT Raised to $10 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight Rating on Eli Lilly (LLY)
-
Aridis Pharmaceuticals to Host Investor Day Showcasing APEX™ Technology Platform and Key Opinion Leader Panels on Cystic Fibrosis and Pneumonia
-
Freddie Mac Announces Pricing of $379 Million Multifamily Small Balance Loan Securitization
-
Canopy Growth (WEED:CN) (CGC) PT Raised to Cdn$32 at Cantor Fitzgerald
-
Endava PLC (ADR) (DAVA) PT Raised to $56 at Cantor Fitzgerald
-
Catalyst Pharmaceutical Partners (CPRX) PT Raised to $12 at Cantor Fitzgerald
-
Agios Pharma (AGIO) PT Raised to $70 at Cantor Fitzgerald
-
Fidelity National Information Services (FIS) PT Raised to $175 at Cantor Fitzgerald
-
Energy Fuels Announces US$16.6 Million Common Share Bought Deal

